We have decided to establish a Ren-Pharm subsidiary, RJW Pharma LLC, which will be focused on Business Development.
While Ren-Pharm activities will remain the same, RJW Pharma LLC will identify partnership opportunities between API Manufacturers and Drug Product Manufacturers, with full alignment of development and launch strategies to maximize results.
As part of this change, we are also very pleased to inform you that Dr. Barbara Galbiati, will be joining RJW Pharma as Executive Advisor/Quality and Regulatory.
Dr. Barbara Galbiati has over 25-year experience in the pharmaceutical industry, including generics, originators, and CDMOs, in the drug product and in the active pharmaceutical ingredient segments.
In addition, Robyn Worrall, Head of Business Development/Strategic Planning, will be returning and joining Barbara at RJW Pharma. For the past 4 ½ years Robyn has focused on the finished dosage side of the business and all it’s related facets specifically focusing on Business Development, closing over 50 deals including licensing, divestments, acquisitions, and co-development opportunities.
At RJW Pharma her main focus will be seeking and evaluating Business Development opportunities focused on the APIs being proposed to and developed by our API partners, and leverage all of her existing relationships all over the world. This will allow us to diversify our activities to meet today’s challenges in both the API and FDF world, with the target to open more doors and increase market share for us and our suppliers.